Skip to main content
SpringerLink
Log in

Immunosuppressive Therapy and Immunomodulation in Stem Cell Transplantation

  • Living reference work entry
  • First Online:
Contemporary Bone Marrow Transplantation

Part of the book series: Organ and Tissue Transplantation ((OTT))

  • 137 Accesses

Abstract

Graft-versus-host disease originates from host immune system’s response to the allogeneic stimuli by donor cells. Clinically graft-versus-host disease is categorized into acute and/or chronic form depending on clinical behaviors. Graft-versus-host disease is one of the major complications of allogeneic stem cell transplantation, leading to significant portion of transplant-related mortality. Various kinds of immunosuppressive agents and immunomodulatory agents have been used to prevent and treat graft-versus-host disease, and new drugs have been studied for this purpose. Conventional approaches include corticosteroid, cyclosporine, tacrolimus, sirolimus, methotrexate, mycophenolate, and antithymocyte globulin. Newer approaches include post-transplant high-dose cyclophosphamide, ibrutinib, and ruxolitinib. This chapter will provide the overview of the most commonly used immunosuppressive and immunomodulatory agents including pharmacology, mechanism of action, clinical use, and toxicities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB (1991) Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 146(10):3523–3527

    CAS  PubMed  Google Scholar 

  • Altmeyer A, Dumont FJ (1993) Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma. Cytokine 5(2):133–143

    Article  CAS  PubMed  Google Scholar 

  • Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80(12): 2964–2968

    Article  CAS  PubMed  Google Scholar 

  • Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB (2012) Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 119(25):6145–6154

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH (2008) Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 26(35):5767–5774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Armitage JM, Kormos RL, Fung J, Starzl TE (1991) The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 23(6):3054–3057

    CAS  PubMed  PubMed Central  Google Scholar 

  • Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, Nash RA, Papayannopoulou T, Storb R, Sullivan KM, Witherspoon R, Deeg HJ (2001) Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72(12):1924–1929

    Article  CAS  PubMed  Google Scholar 

  • Bennett WM, Pulliam JP (1983) Cyclosporine nephrotoxicity. Ann Intern Med 99(6):851–854

    Article  CAS  PubMed  Google Scholar 

  • Bertino JR (1993) Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 11(1):5–14

    Article  CAS  PubMed  Google Scholar 

  • Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, Neglia JP (1996) Malignant neoplasms following bone marrow transplantation. Blood 87(9):3633–3639

    Article  CAS  PubMed  Google Scholar 

  • Bierer BE (1993) Advances in therapeutic immunosuppression: biology, molecular actions and clinical implications. Curr Opin Hematol 1:149

    Google Scholar 

  • Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA (1995) Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85(9):2607–2618

    Article  CAS  PubMed  Google Scholar 

  • Bleyer WA (1977) Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4(2):87–101

    Article  CAS  PubMed  Google Scholar 

  • Borel J (1982) The history of cyclosporin A and its significance. In: White DJG (ed) Cyclosporin A. Elsevier, New York, p 5

    Google Scholar 

  • Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR (1993) Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 13(8):4760–4769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O’Donnell PV (2011) Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118(2):282–288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O’Donnell MR, Parker PM et al (1993) Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329(17):1225–1230

    Article  CAS  PubMed  Google Scholar 

  • Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O’Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Bluzme KG (2000) Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 6(3):254–261

    Article  CAS  PubMed  Google Scholar 

  • Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH (2007) Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109(7): 3108–3114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R (2008) Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 112(12): 4425–4431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH (2014) Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 124(8):1372–1377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR (2014) Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 124(11):4867–4876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fabre G, Goldman ID (1985) Formation of 7-hydroxymethotrexate polyglutamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells, in vitro. Cancer Res 45(1):80–85

    CAS  PubMed  Google Scholar 

  • Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ (1996) FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 87(8):3514–3519

    Article  CAS  PubMed  Google Scholar 

  • Ferrara JL, Deeg HJ (1991) Graft-versus-host disease. N Engl J Med 324(10):667–674

    Article  CAS  PubMed  Google Scholar 

  • Franklin TJ, Cook JM (1969) The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 113(3):515–524

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, Takaya S, Alessiani M, Demetris A, Bronster O et al (1991) A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 23(6): 2977–2983

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gething MJ, Sambrook J (1992) Protein folding in the cell. Nature 355(6355):33–45

    Article  CAS  PubMed  Google Scholar 

  • Giroux M, Delisle JS, Gauthier SD, Heinonen KM, Hinsinger J, Houde B, Gaboury L, Brochu S, Wu J, Hebert MJ, Perreault C (2011) SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage. Blood 117(5):1734–1744

    Article  CAS  PubMed  Google Scholar 

  • Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Gorlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N (2014) Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 15(7):757–766

    Article  CAS  PubMed  Google Scholar 

  • Gluckman E, Lokeic F, Devergie A (1980) Pharmacokinetic monitoring of cyclosporine in allogeneic bone marrow transplants. Transplant Proc 20:122

    Google Scholar 

  • Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM (1996) Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 87(11):4887–4893

    Article  CAS  PubMed  Google Scholar 

  • Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ, Fleming MA, Caron PR, Hsiao K, Navia MA (1995) X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82(3):507–522

    Article  CAS  PubMed  Google Scholar 

  • Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG (1999) Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340(22):1704–1714

    Article  CAS  PubMed  Google Scholar 

  • He YW, Adkins B, Furse RK, Malek TR (1995) Expression and function of the gamma c subunit of the IL-2, IL-4, and IL-7 receptors. Distinct interaction of gamma c in the IL-4 receptor. J Immunol 154(4):1596–1605

    CAS  PubMed  Google Scholar 

  • Hechinger AK, Smith BA, Flynn R, Hanke K, McDonald-Hyman C, Taylor PA, Pfeifer D, Hackanson B, Leonhardt F, Prinz G, Dierbach H, Schmitt-Graeff A, Kovarik J, Blazar BR, Zeiser R (2015) Therapeutic activity of multiple common gamma-chain cytokine inhibition in acute and chronic GVHD. Blood 125(3):570–580

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122(7):1192–1202

    Article  CAS  PubMed  Google Scholar 

  • Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C et al (1990) Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75(4):1011–1016

    Article  CAS  PubMed  Google Scholar 

  • Holler E, Kolb HJ, Wilmanns W (1993) Treatment of GVHD – TNF-antibodies and related antagonists. Bone Marrow Transplant 12(Suppl 3):S29–S31

    PubMed  Google Scholar 

  • Hovi T, Allison AC, Allsop J (1975) Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation of lymphocytes. FEBS Lett 55(1):291–293

    Article  CAS  PubMed  Google Scholar 

  • Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T, McGlave P, Weisdorf D (2007) Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol 47(1):6–12

    Article  CAS  PubMed  Google Scholar 

  • Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV (2018) Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy 10(5):391–402

    Article  CAS  PubMed  Google Scholar 

  • Jaglowski SM, Blazar BR (2018) How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv 2(15):2012–2019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, Mekki QA (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57(3):281–290

    Article  CAS  PubMed  Google Scholar 

  • Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H et al (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 40(9):1256–1265

    Article  CAS  Google Scholar 

  • Lai JH, Tan TH (1994) CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem 269(48):30077–30080

    CAS  PubMed  Google Scholar 

  • Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL (2008) Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111(4):2470–2475

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lewis WD, Jenkins RL, Burke PA, Winn KM, Shaffer D, Lopez R, Monaco AP (1991) FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. Transplant Proc 23(6):2989–2991

    CAS  PubMed  Google Scholar 

  • Locatelli F, Bernardo ME, Bertaina A, Rognoni C, Comoli P, Rovelli A, Pession A, Fagioli F, Favre C, Lanino E, Giorgiani G, Merli P, Pagliara D, Prete A, Zecca M (2017) Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18(8):1126–1136

    Article  CAS  PubMed  Google Scholar 

  • Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641–650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Martel RR, Klicius J, Galet S (1977) Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 55(1):48–51

    Article  CAS  PubMed  Google Scholar 

  • Mekki Q, Lee C, Aweeka F et al (1993) Pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients. Clin Pharmacol Ther 53:238A

    Google Scholar 

  • Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130(21):2243–2250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT (1993) Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 268(5):3734–3738

    CAS  PubMed  Google Scholar 

  • Morris RE, Meiser BM (1989) Identification of a new pharmacologic action for an old compound. Med Sci Res 17:609

    CAS  Google Scholar 

  • Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC (1990) Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22(4):1659–1662

    CAS  PubMed  Google Scholar 

  • Nahas MR, Soiffer RJ, Kim HT, Alyea E, Arnason J, Joyce R, Antin JH, Ho V, Stroopinsky D, Li S, Levine JD, McMasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan E, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan D, Rosenblatt J (2018) Phase I clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. https://doi.org/10.1182/blood-2017-05-780239

  • Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J et al (1995) Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 85(12):3746–3753

    Article  CAS  PubMed  Google Scholar 

  • Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B et al (1989) The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 8(1):1–13

    Article  CAS  PubMed  Google Scholar 

  • Nevill TJ, Tirgan MH, Deeg HJ, Klingemann HG, Reece DE, Shepherd JD, Barnett MJ, Phillips GL (1992) Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 9(5):349–354

    CAS  PubMed  Google Scholar 

  • Nicholson SE, Oates AC, Harpur AG, Ziemiecki A, Wilks AF, Layton JE (1994) Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation. Proc Natl Acad Sci USA 91(8):2985–2988

    Article  CAS  PubMed  Google Scholar 

  • Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM (1994) Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372(6506):570–573

    Article  CAS  PubMed  Google Scholar 

  • Oosterhuis B, ten Berge IJ, Schellekens PT, Koopmans RP, van Boxtel CJ (1986) Prednisolone concentration-effect relations in humans and the influence of plasma hydrocortisone. J Pharmacol Exp Ther 239(3):919–926

    CAS  PubMed  Google Scholar 

  • Petric R, Freeman D, Wallace C, McDonald J, Stiller C, Keown P (1988) Effect of cyclosporine on urinary prostanoid excretion, renal blood flow, and glomerulotubular function. Transplantation 45(5): 883–889

    Article  CAS  PubMed  Google Scholar 

  • Piguet PF, Grau GE, Allet B, Vassalli P (1987) Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166(5):1280–1289

    Article  CAS  PubMed  Google Scholar 

  • Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Cleary K, Champlin R, Besien K, Andersson B, Maher R, Fitzsimmons W (1996) Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 88(11):4383–4389

    Article  CAS  PubMed  Google Scholar 

  • Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92(7): 2303–2314

    CAS  PubMed  Google Scholar 

  • Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O’Donnell M, Krishnan AY, Senitzer D, Forman SJ (2010) A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 115(5):1098–1105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Santos GW, Tutschka PJ, Brookmeyer R et al (1987) Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transpl 1:21

    Google Scholar 

  • Schiff MH, Goldblum R, Rees MMC (1990) 2-Morpholino-ethyl mycophenolic acid (ME-MPA) in the treatment of refractory rheumatoid arthritis. Arthritis Rheum 33(S1):155

    Google Scholar 

  • Schilsky RL, Bailey BD, Chabner BA (1980) Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci USA 77(5):2919–2922

    Article  CAS  PubMed  Google Scholar 

  • Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schonle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Hacker H, Hildebrandt GC, Hacker G, Zeiser R (2014) Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med 20(6):648–654

    Article  CAS  PubMed  Google Scholar 

  • Sehgal SN, Baker H, Vezina C (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 28(10):727–732

    Article  CAS  Google Scholar 

  • Shalaby MR, Fendly B, Sheehan KC, Schreiber RD, Ammann AJ (1989) Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation 47(6): 1057–1061

    Article  CAS  PubMed  Google Scholar 

  • Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N (2014) Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 123(24):3832–3842

    Article  CAS  PubMed  Google Scholar 

  • Storb R, Epstein RB, Graham TC, Thomas ED (1970) Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9(3):240–246

    Article  CAS  PubMed  Google Scholar 

  • Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V et al (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314(12):729–735

    Article  CAS  PubMed  Google Scholar 

  • Storb R, Deeg HJ, Fisher L, Appelbaum F, Buckner CD, Bensinger W, Clift R, Doney K, Irle C, McGuffin R et al (1988) Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 71(2):293–298

    Article  CAS  PubMed  Google Scholar 

  • Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, Leisenring W, Shulman H (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89(8):3048–3054

    Article  CAS  PubMed  Google Scholar 

  • Tefferi A, Pardanani A (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86(12):1188–1191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vallera DA, Panoskaltsis-Mortari A, Jost C, Ramakrishnan S, Eide CR, Kreitman RJ, Nicholls PJ, Pennell C, Blazar BR (1996) Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor. Blood 88(6): 2342–2353

    Article  CAS  PubMed  Google Scholar 

  • Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS (1994) CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 58(5):602–610

    Article  CAS  PubMed  Google Scholar 

  • Watkins B, Qayed M, Bratrude B, Betz K, Brown M, Rhodes J, Sinclair S, Suessmuth Y, Yu A, Hebert K, Pasquini MC, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn DA, Lalefar N, Norkin M, Pulsipher MA, Shenoy S, Blazar B, Langston A, Horan JT, Kean L (2017) T cell Costimulation blockade with Abatacept nearly eliminates early severe acute graft versus host disease after HLA-mismatched (7/8 HLA matched) unrelated donor transplant, with a favorable impact on disease-free and overall survival. Blood 130(Suppl 1):212–212

    Google Scholar 

  • Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D (2003) Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 122(1):128–134

    Article  CAS  PubMed  Google Scholar 

  • Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ (1988) Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 319(2): 65–70

    Article  CAS  PubMed  Google Scholar 

  • Zaharko DS, Fung WP, Yang KH (1977) Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res 37(6):1602–1607

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematologic Malignancies & Cellular Therapy, Duke University, Durham, NC, USA

    Nelson J. Chao & Taewoong Choi

Authors
  1. Nelson J. Chao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taewoong Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taewoong Choi .

Editor information

Editors and Affiliations

  1. Tata Medical Center, Kolkata, West Bengal, India

    Mammen Chandy

  2. CLINICAL HAEMATOLOGY and HCT, Tata Medical Center, Kolkata, West Bengal, India

    Vivek S Radhakrishnan

  3. Oncology Centre of Excellence, Tata Medical Center, Kolkata, West Bengal, India

    Reghu Sukumaran

Section Editor information

  1. Tata Medical Center, Kolkata, India

    Vivek Radhakrishnan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Chao, N.J., Choi, T. (2020). Immunosuppressive Therapy and Immunomodulation in Stem Cell Transplantation. In: Chandy, M., Radhakrishnan, V., Sukumaran, R. (eds) Contemporary Bone Marrow Transplantation. Organ and Tissue Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-64938-2_25-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64938-2_25-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64938-2

  • Online ISBN: 978-3-319-64938-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation